Novo Nordisk (NVO) (OTCPK:NONOF) appears to have forced its CEO, Lars Fruergaard Jørgensen, to resign as the Danish pharma ...

A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the ...

FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...